Antibody-Drug Conjugates

View All

antibody-drug-conjugates-adcs-in-lung-cancer-treatment
A Quick Review of Antibody-Drug Conjugates (ADCs) in Lung Cancer: HER2, TROP-2, HER3, MET, and CEACAM5 ADC Advancements

Lung cancer remains the leading cause of cancer-related death in the United States. The American Cancer Society estimates 238,340 people will be diagnosed with lung cancer in 2023, with non-small cell lung cancer (NSCLC) accounting for the majority of cases (roughly 80% to 85%).The treatment paradigm of antibody-dr...

Find More

antibody-drug-conjugates-adcs-in-oncology
Antibody-drug Conjugates in Oncology: An Overview of the Current and Future Treatment Landscape

Antibody-drug conjugates (ADCs) are becoming more prominent in the cancer treatment market. Antibody-drug conjugates are one of the most rapidly increasing anticancer treatments. This approach uses a mAb attached to a cytotoxic payload via a chemical linker that is directed towards a target antigen expressed on the...

Find More

roche-polivy-adc-for-dlbcl-treatment
Roche’s CD79b ADC POLIVY: Attempt to Change DLBCL Treatment Space

In recent years, the field of oncology has witnessed a remarkable transformation thanks to the groundbreaking innovation of antibody-drug conjugates (ADCs). These game-changing molecules have three key components: an antibody drug, a potent cytotoxic payload, and a specialized linker protein that binds them togethe...

Find More

Bladder Cancer Highlights ASCO
Seagen/Astellas plans to expand their Antibody Drug Conjugate (ADC), Padcev in additional bladder cancer settings?

Padcev (Enfortumab vedotin) for the treatment of locally advanced or metastatic urothelial cancer, Adcetris (Brentuximab vedotin) for the treatment of several types of CD30-expressing lymphomas, and Tivdak (Tisotumab vedotin) for the treatment of recurrent or metastatic cervical cancer are the three ADCs that Seage...

Find More

antibody-drug-conjugate-pipeline
Insights into the Evolving Landscape of Antibody-Drug Conjugate (ADC) & the Key Companies in the Segment

In the year 2000, the first-ever Antibody-drug Conjugate (ADC) - Mylotarg, was launched by Pfizer and was considered a miracle in cancer treatment. And it appeared like there was no looking back for these antibody-drug conjugates. But it took almost another 11 years for the next ADC to launch in the market - Adectr...

Find More

Intellia's Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly's Diabetes Blockbuster Tirzepatide; Polyphor’s Bleak Future
Intellia’s Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly’s Diabetes Blockbuster Tirzepatide; Polyphor’s Bleak Future

A New Dawn for CRISPR, Intellia Edits Cells Inside the Body Intellia Therapeutics, along with its partner Regeneron Pharmaceuticals, recently announced its successful attempt in editing the cells inside the body leveraging the CRISPR technique. The world’s first-ever trial that has their DNA edited through an in...

Find More

Johnson & Johnson
4D Molecular Therapeutics raises; Arvinas slates for IPO; Sutro ruminates for $ 75M; Emergent BioSolutions remunerates Narcan maker

Gene therapy company 4D Molecular Therapeutics raises USD 90 Million to collaborate with AstraZeneca and Roche for moving gene therapies into clinical testing 4D Molecular Therapeutics has upraised USD 90 million in venture capital funds for progressing its vector platform and treatments, which use adeno-associate...

Find More

Delveinsight
Sutro nets $85.4M; HiFiBiO pens Takeda R&D collaboration

Sutro Biopharma nets $85.4M to drive antibody-drug conjugates Sutro Biopharma reeled in an $85.4 million series E that will advance some early-stage programs as well as its cancer pipeline, which includes a pair of antibody-drug conjugates (ADCs).Of its ADC assets, STRO-001 is in phase 1 for lymphoma and multiple my...

Find More

The next generation of ‘weaponized antibody’ therapies

Efforts to develop antibodies that can ferry drugs into cancer cells and minimize damage to healthy tissue are gathering steam. The next generation of these ‘weaponized antibody’ therapies, called antibody–drug conjugates (ADCs), is working its way through clinical trials. The concept that underlies these drugs is s...

Find More

DelveInsight’s Oncology based Reports, 2015

DelveInsight, the leading market research and consulting company has added Oncology based Reports to its portfolio. With this launch DelveInsight now has 100+ Oncology based Reports. In addition to this, our research expertise provides our clients with up to date information of market till the date on which order is...

Find More